Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA) identifier:
NCT04038502 (

Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Study Contact Information:

For additional information, please contact:

Robert B Montgomery, MD by phone: 206-277-6878  or by email: [email protected]    
Makayla L DeJong by phone: (206) 277-4527 or by email: [email protected] 


About the Study

This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.

What the Study Involves

Participants will be assigned to one of two different groups, and both the participant and their doctors will know which treatment  they are receiving. 

Participants can crossover to the other therapy as long as they still meet inclusion criteria and it has been 3 weeks since their last treatment of either carboplatin or olaparib. Throughout the study, safety and the ability of participants to tolerate the treatment will be measured.

Study Sites


Washington DC




New York

North Carolina




This Study is Open To:

Men 18 years or older with the following may be able to participate: 

This Study is Not Open To:

Men with the following may not participate:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.